Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Marylene Clausse"'
Autor:
Amélie Deleporte, Marc Van den Eynde, Frédéric Forget, Stéphane Holbrechts, Thierry Delaunoit, Ghislain Houbiers, Hassan R. Kalantari, Stéphanie Laurent, Erik Vanderstraeten, Marc De Man, Philippe Vergauwe, Marylene Clausse, Jacques Van Der Auwera, Lionel D’Hondt, Pascal Pierre, Bjorn Ghillemijn, Angelique Covas, Marianne Paesmans, Lieveke Ameye, Ahmad Awada, Francesco Sclafani, Alain Hendlisz
Publikováno v:
Cancer Medicine, Vol 10, Iss 13, Pp 4366-4374 (2021)
Abstract Background While docetaxel/cisplatin/5‐fluorouracil (DCF) outperforms CF in first‐line gastric adenocarcinoma, toxicity remains an issue. Methods This multicenter phase II trial randomized chemonaïve metastatic gastric adenocarcinoma pa
Externí odkaz:
https://doaj.org/article/06c577acc47b4f5695fc7987fb553200
Autor:
Marc De Man, Pascal Pierre, Erik Vanderstraeten, Ghislain Houbiers, Lionel D'Hondt, Jacques Van Der Auwera, Hassan Rezaei Kalantari, Amélie Deleporte, Ahmad Awada, Lieveke Ameye, Alain Hendlisz, Thierry Delaunoit, Stéphanie Laurent, Francesco Sclafani, Bjorn Ghillemijn, Marylene Clausse, Marianne Paesmans, Angelique Covas, Marc Van den Eynde, Frédéric Forget, Philippe Vergauwe, Stéphane Holbrechts
Publikováno v:
Cancer medicine, Vol. 10, no. 13, p. 4366-4374 (2021)
Cancer Medicine, Vol 10, Iss 13, Pp 4366-4374 (2021)
Cancer Medicine
Cancer Medicine, Vol 10, Iss 13, Pp 4366-4374 (2021)
Cancer Medicine
Background While docetaxel/cisplatin/5‐fluorouracil (DCF) outperforms CF in first‐line gastric adenocarcinoma, toxicity remains an issue. Methods This multicenter phase II trial randomized chemonaïve metastatic gastric adenocarcinoma patients to
Autor:
Giacomo Bregni, Andrea Pretta, Chiara Senti, Elena Acedo Reina, Caroline Vandeputte, Elena Trevisi, Paraskevas Gkolfakis, Pashalina Kehagias, Amélie Deleporte, Jean-Luc Van Laethem, Philippe Vergauwe, Marc Van den Eynde, Guido Deboever, Jos Janssens, Gauthier Demolin, Stephane Holbrechts, Marylene Clausse, Thierry De Grez, Marc Peeters, Lionel D'Hondt, Karen Geboes, Tatiana Besse-Hammer, Françoise Rothé, Patrick Flamen, Alain Hendlisz, Francesco Sclafani
Publikováno v:
Acta oncologica
Acta oncologica (Stockholm, Sweden), Vol. 61, no. 10, p. 1223-1229 (2022)
Acta oncologica (Stockholm, Sweden), Vol. 61, no. 10, p. 1223-1229 (2022)
Background While circulating tumour (ct)DNA is an indicator of minimal residual disease and negative prognostic factor in stage II-III colon cancer, no study has ever analysed the value of this biomarker in colon cancer patients treated with neoadjuv
Autor:
Françoise Rothé, Giacomo Bregni, Elena Trevisi, Pashalina Kehagias, Caroline Vandeputte, Chiara Senti, Jean-Luc Van Laethem, Gauthier Demolin, Francesco Sclafani, Paraskevas Gkolfakis, Marylene Clausse, Karen Geboes, Alexis Buggenhout, T. Besse-Hammer, Marc Van den Eynde, Elena Acedo Reina, L. D'Hondt, Stéphane Holbrechts, Guido Deboever, Philippe Vergauwe, Thierry De Grez, Jos Janssens, Amélie Deleporte, Marc Peeters, Andrea Pretta, Patrick Flamen, Alain Hendlisz
Publikováno v:
Cancer Research. 81:28-28
Introduction Circulating tumour (ct)DNA is an indicator of minimal residual disease and negative prognostic factor in stage II-III CC treated with surgery +/- adjuvant chemotherapy. No study, however, has ever analysed the prognostic value of this bi
Autor:
Jos Janssens, Giacomo Bregni, Patrick Flamen, Chiara Senti, Lionel D'Hondt, Marylene Clausse, Stéphane Holbrechts, Karen Geboes, Thierry De Grez, Francesco Sclafani, Caroline Vandeputte, T. Besse-Hammer, Alain Hendlisz, Philippe Vergauwe, Jean-Luc Van Laethem, Paraskevas Gkolfakis, Françoise Rothé, Marc Van den Eynde, Elena Acedo Reina, Gauthier Demolin
Publikováno v:
Journal of Clinical Oncology. 39:3600-3600
3600 Background: ctDNA is an indicator of minimal residual disease and negative prognostic factor in stage II-III CC treated with surgery +/- adjuvant chemotherapy (CT). No study, however, has ever analysed the prognostic value of this biomarker in C
Autor:
Thierry Gil, Peter Schatteman, Marylene Clausse, Jan Van Haverbeke, Joanna Van Erps, Jeroen Mebis, Wim Demey, Marika Rasschaert, Dirk Schrijvers, Lionel D'Hondt, Els Everaert, W. Wynendaele, Bertrand Filleul, Sylvie Rottey, Filip Van Aelst, Joanna Vermeij, Fransien Van Hende, Patrick Werbrouck, Jean-Charles Goeminne, Charles Van Praet, Gino Pelgrims, Nicolaas Lumen, Jolanda Verheezen, Jean Pascal Machiels, Denis Schallier
Publikováno v:
Clinical Genitourinary Cancer
Individual patients' survival varies greatly in metastatic castration-resistant prostate cancer. Retrospective analysis of 368 patients treated with docetaxel and starting abiraterone acetate revealed 5 adverse prognostic factors: hemoglobin < 12 g/d
Autor:
Patrick Flamen, Marianne Paesmans, Amélie Deleporte, Jean-Luc Van Laethem, Philippe Vergauwe, Alain Hendlisz, Karen Geboes, Thierry De Grez, Jozef Janssens, T. Besse-Hammer, Alexis Buggenhout, Rafael Caparica, Marylene Clausse, Guido Deboever, Joanna Vermeij, Stéphane Holbrechts, Martine Piccart, Gauthier Demolin, L. D'Hondt, Marc Van den Eynde
Publikováno v:
Journal of Clinical Oncology. 37:3610-3610
3610 Background: Although being the standard-of-care for stage III colon cancer, no biomarkers can identify patients (pts) who benefit from adjuvant chemotherapy. In metastatic pts, the lack of metabolic response (mR) in FDG-PET/CT after 1 chemothera
Autor:
Sylvie Rottey, Joanna Van Erps, Joanna Vermeij, Patrick Werbrouck, Peter Schatteman, Bertrand Filleul, Lionel D'Hondt, W. Wynendaele, Fransien Van Hende, Dirk Schrijvers, Denis Schallier, Jean-Charles Goeminne, Gino Pelgrims, Els Everaert, Wim Demey, Filip Van Aelst, Jolanda Verheezen, Jean Pascal Machiels, Marika Rasschaert, Thierry Gil, Marylene Clausse, Charles Van Praet, Jan Van Haverbeke, Nicolaas Lumen, Jeroen Mebis
Publikováno v:
Urologic Oncology : seminars and original investigations, Vol. 34, no. 6, p. 254.e7-254.e13 (2016)
Urologic oncology
Urologic oncology
Background: Abiraterone acetate (AA) is licensed for treating metastatic castration-resistant prostate cancer (mCRPC). Real-world data on oncological outcome after AA are scarce. The current study assesses efficacy and safety of AA in mCRPC patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6865f0f45657ada1d6ceab9ba0a47ee0
https://biblio.vub.ac.be/vubir/abiraterone-acetate-postdocetaxel-for-metastatic-castrationresistant-prostate-cancer-in-the-belgian-compassionate-use-program(5db35800-353a-4c9a-b822-366d75633640).html
https://biblio.vub.ac.be/vubir/abiraterone-acetate-postdocetaxel-for-metastatic-castrationresistant-prostate-cancer-in-the-belgian-compassionate-use-program(5db35800-353a-4c9a-b822-366d75633640).html
Autor:
D. Verhoeven, Lionel D'Hondt, N. Whenham, Olivier Feron, P. Glorieux, Catherine Dopchie, Samuel Branders, J. Schoonjans, Sylvie Rottey, Pierre Dupont, Emmanuel Seront, J-L Canon, Joseph Kerger, Marylene Clausse, Vincent Verschaeve, Jean-Marie Vandenbulcke, Jean-Pascal Machiels, Brieuc Sautois, J. C. Goeminne
Publikováno v:
Annals of Oncology. 23:2663-2670
Background: This phase II study assessed the safety and efficacy of everolimus, an oral mammalian target of rapamycin inhibitor in advanced transitional carcinoma cell (TCC) after failure of platinum-based therapy. Patients and methods: Thirty-seven
Autor:
D. Schallier, Linda Dhondt, Peter Schatteman, J. Van Haverbeke, S. Rottey, D. Schrijvers, Els Everaert, F. Van Aelst, Jolanda Verheezen, Joanna Vermeij, Thierry Gil, Marylene Clausse, C. Van Praet, J. C. Goeminne, Patrick Werbrouck, Jeroen Mebis, Nicolaas Lumen, Bertrand Filleul, Wim Demey, F. Van Hende, J. Van Erps, W. Wynendaele, Gino Pelgrims, Marika Rasschaert, J-P. Machiels
Publikováno v:
European Urology Supplements. 15:e772-e772a